Gilead Sciences Gilead Sciences (NASDAQ: GILD) And Galapagos To Halt ISABELA Phase 3 Trial Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos (NASDAQ: GLPG) have disclosed that they both intend to stop Phase 3 clinical studies with the trial autotaxin inhibitor ziritaxestat in sufferers with idiopathic pulmonary fibrosis.
